<DOC>
	<DOC>NCT01806636</DOC>
	<brief_summary>This registry is a post market observational, prospective, multi-center registry. It is designed to evaluate patient experience with the RePneu™ device for the relief of the emphysema symptoms and the continued collection of safety and effectiveness data on this CE Mark product. In addition, the registry will collect information that will serve as the foundation for a cost effectiveness analysis.</brief_summary>
	<brief_title>Post Market Observational, Prospective, Multi-center Study</brief_title>
	<detailed_description />
	<mesh_term>Emphysema</mesh_term>
	<criteria>All adult patients diagnosed with homogeneous or heterogeneous emphysema who are appropriate for Coil treatment based on the CEMark Approved IFU and who have been scheduled for treatment with the RePneu procedure RV of &gt;175% predicted Post bronchodilator FEV1 of ≤45% predicted. Normal international normalized ratio (INR) in the absence of anticoagulation therapy Participant read, understood and signed the Informed Consent form Known uncontrolled pulmonary hypertension defined by systolic RVP &gt;50mmHg Giant bullae &gt; 1/3 lung volume Patients on antithrombotic treatment (except for aspirin) which cannot be stopped 7 days prior to treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Coil</keyword>
	<keyword>RePneu</keyword>
	<keyword>PneumRx</keyword>
	<keyword>LVRC</keyword>
</DOC>